Abstract: Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloalkyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4 is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof. Also provided are small molecule selective aromatase inhibitors having a molecular weight of less 500 g/mol. In some embodiments, the small molecule selective aromatase inhibitors described herein have a molecular weight of less than 450 g/mol. Also provided are methods for suppressing aromatase activity expression in cancer cells comprising the step of administering a pharmaceutically effective amount of a small molecule aromatase inhibitor to a subject in need of such treatment. In one embodiment, the cancer cells are breast cancer cells.

Abstract: Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloalkyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4 is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof Also provided are small molecule selective aromatase inhibitors having a molecular weight of less 500 g/mol. In some embodiments, the small molecule selective aromatase inhibitors described herein have a molecular weight of less than 450 g/mol. Also provided are methods for suppressing aromatase activity expression in cancer cells comprising the step of administering a pharmaceutically effective amount of a small molecule aromatase inhibitor to a subject in need of such treatment. In one embodiment, the cancer cells are breast cancer cells.

Abstract: The invention relates to a method for inducing systemic resistance in plants, thereby protecting plants against a broad range of plant pathogens and disease. The method of the invention comprises the application of a biologically active formulation, comprising a diphenyl ether, to a plant. In accordance with the invention, it has been observed that use of this formulation results in induced systemic resistance in a target plant. Also in accordance with the method of the invention, the formulation has been shown to trigger long-lasting, non-specific systemic resistance in the plant to a variety of pathogens and disease. Furthermore, the method of the invention results in an increase in the levels of plant isoflavones.

Abstract: Methods for increasing the levels of isoflavones in plants are provided. The method comprise applying a biologically effective amount of composition comprising a select nuclear receptor ligand to the plant. Compositions for inducing the production of isoflavones in plants are also provided. Such compositions comprise one or preferably, a combination of the select nuclear receptor ligands. The compositions also comprise a compound that enhances the capacity of the plant to release daidzein and/or utilize it for the production of glyceollin. The action of such a compound is complementary to that of the nuclear receptor ligand.